AGENDA

Clinical Oncology Operations Roundtable Q1 Strategy Meeting 2021

February 2021

All times are in EDT

The Clinical Oncology Operations Roundtable Meeting offers the opportunity for attendees to actively engage in stimulating discussions on major themes in the oncology clinical trials arena, taking away valuable lessons and creating lasting connections.

The format will allow senior-level, small-sided engagement between the host vendor with 10-20 handpicked, invite-only, trial sponsor representatives, and deliver a much high-quality discussion over the 45 minute roundtables that they could hope to achieve at an event, in-person or virtually.

The headline speakers we will deliver for the pre and post-roundtable sessions will offer an insightful analysis of the trends and challenges from the past year as well as a forward-thinking projection of where the industry is heading.

10th February 2021	
08:45	*Registration*
09:00	*OPENING KEYNOTE* **What does Covid-19 exposure mean for cancer patient health and clinical trials?** • Uncovering the ways that the Covid-19 virus threatens patient safety and validity of clinical data and how to overcome this in your clinical trial strategy • Considering the scenario whereby a patient is exposed to coronavirus and whether that disrupts the validity of their drug response in an oncology trial • Looking ahead at the long-term implications of Covid-19 infection and if this could lead to an increase in cancer prevalence and other health conditions; will this shape the pharmaceutical industry and future of clinical trials? *Jason Litten, Chief Medical Officer, Artiva Biotherapeutics*
09:45	**Roundtable round 1**
10:45	**Roundtable round 2**
11:45	**Roundtable round 3**

12:00	Meeting Allocation
13:00	*CLOSING KEYNOTE* Regulatory spotlight: pathways for expedited drug approvals in oncology • Focusing on the latest updates on expedited pathways for oncology programs and thinking strategically about how to deal with them from a regulatory point of view • Analysing how the FDA's regulatory framework is evolving and what this means for trial sponsors • Outlining the FDA's established and pilot programs and what different pathways are available for oncology companies • Providing advice on early planning and a solid regulatory strategy to get your drug to patients quicker *Sunni Miller, Executive Director, Regulatory Affairs, Gossamer Bio*

Roundtable Titles:

Each table runs 3 times on the same topic. Tables are exclusive, other vendors cannot attend. Minimum 10 participants for each table.

Attendees can select up to 3 roundtables.

1. Imaging in Oncology Studies
2. Clinical Data Collection & Management
3. CRO and Clinical Trial FSP Selection for SME Oncology companies
4. Clinical Oncology Trials in Europe
5. Patient Recruitment, Retention, and Engagement
6. Patient Centricity & Engagement
7. Clinical Site Management in Oncology studies
8. Early and Expanded Access Programs
9. Clinical Oncology Regulatory Landscape

For sponsorship opportunities please contact: Conor.Taylor@arena-international.com

For programme enquiries please contact: Amy.Malkani@arena-international.com